Sun Pharma and Philogen enter into licensing agreement for Nidlegy™

Attention Investors

Kindly note the Change in PAY IN for BSE A/C No. : 1201250000000691 (CDSL), if you have an NSDL A/C, kindly use INTER DEPOSITORY SLIP. For assistance, please call OR contact: Mr. Dadu, 98339 89807 / 022-6145 1000. | Exchanges / Depository: Prevent Unauthorized Transactions in your Trading / Demat account --> Update your Mobile Numbers / email IDs with your Stock Brokers / Depository Participant. Receive alerts on your Registered Mobile / email IDs for trading account transactions and all debit and other important transactions in your demat account directly from Exchange / Depository on the same day ......................Issued in the interest of Investors." | KYC : "KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary." | ASBA-IPO : "No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

- EQUITY
  EQUITY
  PRICE
  
  Gainers & Losers
  
  Advances & Declines
  
  New Highs & Lows
  
  Index Movers
  
  Only Buyers/Sellers
  
  Out/Under Performers
- NEWS
  CORPORATE ACTIONS
  
  Announcements
  
  Book Closure
  
  Board Meetings
  
  Bonus Issues
  
  Rights Issues
  
  De-Listed Shares
  
  Market Turnover
  
  Change of Name
  
  Split of Face Value
- OTHER MARKETS
  FII Investments
  
  MF Investments
  
  ADR Prices
  
  World Indices
  
  Forex
  
  CORPORATE INFO
- VOLUME
  VOLUME
  Value & Volume Toppers
  
  Unusual Volume
  
  Bulk & Block Deals
  
  Sector Watch
- ANALYSIS
  ANALYSIS
  52 Week High Low
  
  Live Indices
  
  Exchange Holidays
  
  Index Constituents
  
  Historical Returns
  
  Circuit Breakers
- IPO
  IPO
  
  Forthcoming Issues
  
  Open Issues
  
  Closed Issues
  
  New Listing
  
  Basis of Allotment
  
  Draft Prospectus
  
  New Issue Monitor
  
  Best Performers
  
  Know IPO's / FAQ's

Thursday, April 25, 2024 2:52:00 PM

Asian Paints

2864.55

(-0.10%)

Axis Bank

1124.00

(5.67%)

Bajaj Finance

7328.65

(0.01%)

Bajaj Finserv

1660.85

(1.86%)

Bharti Airtel

1338.85

(0.19%)

HCL Technologi..

1506.20

(1.79%)

HDFC Bank

1513.45

(0.17%)

Hind. Unilever

2233.50

(-1.14%)

ICICI Bank

1119.55

(2.07%)

IndusInd Bank

1496.85

(1.51%)

Infosys

1438.10

(0.44%)

ITC

436.40

(1.76%)

JSW Steel

908.40

(2.88%)

Kotak Mah. Ban..

1638.40

(-11.10%)

Larsen & Toubr..

3648.00

(0.36%)

M & M

2107.65

(2.35%)

Maruti Suzuki

12946.40

(0.05%)

Nestle India

2559.45

(2.26%)

NTPC

358.60

(2.01%)

Power Grid Cor..

293.15

(0.89%)

Reliance Indus..

2932.00

(1.08%)

St Bk of India

811.20

(4.91%)

Sun Pharma.Ind..

1512.35

(1.75%)

Tata Motors

999.75

(0.82%)

Tata Steel

167.05

(0.94%)

TCS

3855.50

(0.63%)

Tech Mahindra

1190.30

(0.35%)

Titan Company

3579.30

(-0.78%)

UltraTech Cem.

9692.10

(0.35%)

Wipro

461.50

(0.28%)

	Equity Analysis

	News Analysis

	Corporate Actions

	Other Market

	Company Profile

Share Holding Pattern

Your results on : Equity | News | Company-News

Sun Pharma and Philogen enter into licensing agreement for Nidlegy™	Share Back
(30 May 2023)
Sun Pharmaceutical Industries and Philogen S.p.A (BIT: PHIL) today announced that they have entered into a licensing agreement for commercializing Philogen's specialty product, Nidlegy™ (Daromun) in the territories of Europe, Australia and New Zealand. Nidlegy™, currently in Phase III clinical trials, is a new anti-cancer biopharmaceutical which is being developed by Philogen for the treatment of melanoma and non-melanoma skin cancers. Under the terms of the agreement, Sun Pharma will have exclusive rights to commercialise Nidlegy™ for indications of skin cancers in the territories of Europe, Australia and New Zealand. Philogen will complete pivotal clinical trials for the product in Europe, pursue Marketing Authorization with the regulatory authorities and manufacture commercial supplies. Sun Pharma will be responsible for commercialization activities. The two partner companies will share post-commercialization economics in about 50:50 ratio. Other financial terms were not disclosed. Philogen will retain the IP rights for Nidlegy™ for other territories and indications other than skin cancers.
Top